A clinical-stage biotech developing psychedelic-inspired drugs for mental health conditions like depression and anxiety, with a pipeline spanning nasal, oral, and film formulations.
No revenue; the company burns cash, with net losses of USD 0.66B in 2025 and operating losses around USD 0.10B annually, funded by investors rather than product sales.
Its drug candidates face long clinical timelines and regulatory hurdles, but competitors like Compass Pathways and MindMed are advancing similar psychedelic treatments, so any edge is unproven and easily challenged.
Key events, in time order
Cathie Wood's fund sold ATAI shares post-acquisition news while adding Compass Pathways, showing institutional repositioning
Analysts note J&J and AbbVie declined to bid before Lilly deal, raising doubts on rationale
Model update after last patient dosed in Elumina Phase 2 for VLS-01 in MDD
None yet
None yet
Atai is mentioned in a recap of negative analyst comments, indicating a bearish sentiment from at least one source.
Main discussion
RECAP 8/17 -Neg Comments: $ENVX - William Blair $EYPT - Cantor, JPMorgan $LNTH - B Riley $ATAI - Oppy $FTK - WolfPack $IPAR - BWS Financial $YSS - Canaccord Live Breaking trading news https://www.openoutcrier.com
Cathie Wood’s Ark Invest made several major portfolio moves Monday, buying more Nvidia ($NVDA) while selling shares of AMD ($AMD) and Palantir ($PLTR). The trades show Ark continuing to shift capital within the artificial intelligence sector. Ark purchased 101,356 Nvidia shares t
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
